Albireo Pharma Hopeful to Commercialize its PFIC Treatment by the End of the Year
Albireo Pharma, spun out of AstraZeneca, has long been working on developing potential and efficient treatment drugs for the patients suffering from progressive familial intrahepatic cholestasis (PFIC), a rare disorder that leads to insidious liver failure. Now, it seems the dream of the company might come true.
Positive results of Phase III trial PEDFIC 1 presented at the American Association for the Study of Liver Diseases’ annual meeting demonstrated some promising outcomes. The data showed that the treatment with odevixibat, a potent, non-systemic ileal bile acid tr...
